Trial Profile
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2023
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 02 Jan 2023 Primary endpoint has not been met. (Percentage of Participants Achieving At Least a 75=% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16),as per Results published in the Dermatology and Therapy
- 02 Jan 2023 Results published in the Dermatology and Therapy
- 21 May 2021 Status changed from active, no longer recruiting to completed.